Sayed S Daoud
Director, Pharmaceutical Sciences Graduate Programs,
Washington State University Health Sciences, USA
Dr. Daoud will be the Principal Investigator of this project, The goal of the proposed research is to define the epigenetic signatures of HCV disease progression to an early stage of HCC in clinical samples obtained from Egyptian patients using an integrated approach of DNA methylation and CGH array technologies. The epigenetic/genetic signatures of the identified targets could then be used as markers for prognosis and diagnosis of the disease as well as targets for new and innovative approaches to the prevention and treatment of HCC especially that a prophylactic vaccine for HCV infection is not yet available. His administrative experience as the PI of two previously funded grants in the similar areas of research SG Komen and DoD as well as his tenure as Associate Professor of Pharmacology attest to his ability to meet the administrative needs of the proposed project. His membership in the Center for Integrated Biotechnology CIB assure that the assembled team will have access to a wide range of expanding resources. Dr. Daoud is also the editor of a newly published book in an area relevant to the proposed research titled “Cancer Proteomics: From Bench to Bedside” by Humana Press 2008. Thus the current application builds logically on his prior work in the area of genomics and proteomics of cancer and he has chosen coinvestigators Drs Zekri Esmat Bahnassy Dasgupta Shaffer and Skinner to provide additional expertise needed for the success of the application. In summary Dr. Daoud has a demonstrated record of successful and productive research projects in an area of high relevance to the health of the US population and his expertise and experience has prepared him to lead the proposed project.
The overall objective of our research program is in Cancer Therapeutics with major emphasis on integrating Genomics and Proteomics in the Molecular Pharmacology of Cancer.